Brainstorm Cell Therapeutics Inc
BCLI1.170USD
0.0000.00%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
9.26MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Brainstorm Cell Therapeutics Inc Unternehmen
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
Brainstorm Cell Therapeutics Inc Informationen
BörsenkürzelBCLI
Name des UnternehmensBrainstorm Cell Therapeutics Inc
IPO-datumMay 28, 2003
CEOMr. Chaim Lebovits
Anzahl der mitarbeiter27
WertpapierartOrdinary Share
GeschäftsjahresendeMay 28
Addresse1325 Avenue Of Americas
StadtNEW YORK
BörseUS 'Other OTC' and Grey Market
LandUnited States of America
Postleitzahl10019
Telefon12014880460
Websitehttps://brainstorm-cell.com/
BörsenkürzelBCLI
IPO-datumMay 28, 2003
CEOMr. Chaim Lebovits
Führungskräfte von Brainstorm Cell Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
44.15K
--
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Dr. Ibrahim B. (Bob) Dagher, M.D.
Dr. Ibrahim B. (Bob) Dagher, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Prof. Jacob A. Frenkel, Ph.D.
Prof. Jacob A. Frenkel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Menghisteab (Menghis) Bairu, M.D.
Dr. Menghisteab (Menghis) Bairu, M.D.
Independent Director
Independent Director
--
--
Dr. Anthony John (Tony) Polverino, Ph.D.
Dr. Anthony John (Tony) Polverino, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
44.15K
--
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: 3 hours ago
Aktualisiert: 3 hours ago
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Ruck (Matthew J)
2.50%
Lebovits Chaim
1.82%
ACC International Holdings, Ltd.
1.21%
Dagher (Ibrahim B.)
0.72%
Yablonka (Uri)
0.62%
Andere
93.13%
Aktionäre
Aktionäre
Anteil
Ruck (Matthew J)
2.50%
Lebovits Chaim
1.82%
ACC International Holdings, Ltd.
1.21%
Dagher (Ibrahim B.)
0.72%
Yablonka (Uri)
0.62%
Andere
93.13%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
8.44%
Holding Company
1.21%
Investment Advisor
0.02%
Andere
90.33%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
81
2.42K
0.02%
-1.20M
2025Q3
92
137.97K
1.25%
-1.09M
2025Q2
115
2.33M
29.32%
+762.13K
2025Q1
116
2.29M
28.90%
+743.86K
2024Q4
114
1.19M
21.02%
-226.10K
2024Q3
109
1.22M
22.61%
-265.31K
2024Q2
109
1.32M
25.54%
+439.02K
2024Q1
108
855.32K
19.26%
-132.87K
2023Q4
109
841.70K
26.44%
-125.02K
2023Q3
116
902.82K
33.14%
-178.28K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Ruck (Matthew J)
275.84K
2.5%
+275.84K
--
Nov 13, 2024
Lebovits Chaim
200.96K
1.82%
--
--
Apr 01, 2025
ACC International Holdings, Ltd.
133.39K
1.21%
--
--
Apr 01, 2025
Dagher (Ibrahim B.)
79.52K
0.72%
--
--
Apr 01, 2025
Yablonka (Uri)
68.46K
0.62%
--
--
Apr 01, 2025
Hartounian (Hartoun)
52.00K
0.47%
--
--
Apr 01, 2025
Patlis (Alla)
44.35K
0.4%
+40.00K
+919.54%
Jan 01, 2025
Lindborg (Stacy R)
44.15K
0.4%
--
--
Apr 01, 2025
Frenkel (Jacob A.)
43.78K
0.4%
--
--
Apr 01, 2025
Arbel (Irit)
41.05K
0.37%
--
--
Apr 01, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Datum
Ex-Dividendentag
Art
Verhältnis
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
